Clinical Significance and Associations of Stress Hyperglycemia in Severe Fever with Thrombocytopenia Syndrome Authors: Hongyan Song, Zhiye Xu, Xiaofang Chen, Wenqin Chen, Hongling Ye, Yuan Liu, Hong Yan, Sen Wang Published: 2026 ABSTRACT AbstractBackgroundSevere fever with thrombocytopenia syndrome (SFTS) is a highly fatal infectious disease characterized by cytokine storm and multiple organ dysfunction. Stress hyperglycemia is common in severe infections, but its clinical significance in SFTS remains unclear.ObjectiveTo evaluate blood glucose alterations in SFTS and their associations with disease severity, inflammation, and outcomes.MethodsWe retrospectively analyzed 172 SFTS patients. Blood glucose levels, HbA1c, and the stress hyperglycemia ratio (SHR) were assessed at various time points during hospitalization, and their correlations with disease severity, prognosis, and laboratory parameters, including inflammatory cytokines, were analyzed.ResultsAdmission blood glucose and SHR were significantly elevated in SFTS patients compared with controls. Severe and non-surviving patients showed higher blood glucose and SHR levels than mild and surviving patients. Longitudinal analysis revealed persistently elevated or increasing blood glucose levels in non-survivors, whereas survivors showed a declining trend. Blood glucose was positively correlated with viral load, organ dysfunction indicators, coagulation abnormalities, platelet changes, and inflammatory cytokines (IL-1β, IL-6, TNF-α).ConclusionStress hyperglycemia is common in SFTS and is associated with disease severity, inflammatory responses, and adverse clinical outcomes. Blood glucose and SHR may serve as useful markers reflecting disease severity and clinical status in patients with SFTS.Keywords: severe fever with thrombocytopenia syndrome, blood glucose, Dabie bandavirus, stress hyperglycemia, biomarker Introduction Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by Dabie bandavirus, a novel member of the Bunyavirales order.1 In recent years, SFTS has attracted global attention due to its increasing incidence and high fatality rate. SFTS was first recognized and named in 2009 in a patient presenting with persistent high fever, malaise, and thrombocytopenia.2 Since then, an increasing number of cases have been reported, particularly in China, Japan, and South Korea.3,4 SFTS cases occur sporadically, predominantly in rural mountainous and hilly regions, with a peak incidence in summer and a generally susceptible population. Dabie bandavirus is a negative-sense single-stranded RNA virus, primarily transmitted via tick vectors, which infect humans, livestock, and wild animals, thereby facilitating viral circulation.5,6 The clinical manifestations of SFTS include abrupt onset of high fever, fatigue, headache, muscle and joint pain, and marked thrombocytopenia. Patients frequently exhibit hemorrhagic manifestations, such as epistaxis, petechiae, ecchymosis, and gum bleeding. Severe cases may progress to gastrointestinal hemorrhage, neurological symptoms, and multiple organ failure.7 Although the clinical features of SFTS resemble those of other viral hemorrhagic fevers, SFTS shows a more rapid progression and higher case-fatality rate.8 The underlying mechanisms of Dabie bandavirus infection remain incompletely understood, and currently, no specific antiviral therapy or effective vaccine is available. Thus, precise evaluation of disease severity and accurate prediction of progression are crucial. Stress hyperglycemia refers to a transient elevation of blood glucose levels caused by acute stress, such as infections, extensive burns, or traumatic brain injury. It is typically defined as a blood glucose level above 180 mg/dl in patients without pre-existing diabetes.9,10 Viral infections can trigger stress hyperglycemia through interconnected pathways involving inflammation, hormonal changes, and metabolic dysregulation.11,12 Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF‑α), interleukin‑6 (IL‑6), and interleukin‑1 beta (IL‑1β) interfere with insulin signaling by inhibiting insulin receptor substrate proteins, thereby reducing blood glucose uptake in muscle and adipose tissues and promoting hepatic gluconeogenesis, leading to increased blood glucose production.13,14 In this context, SFTS is characterized by excessive immune activation and cytokine storm, with elevated levels of proinflammatory cytokines such as TNF-α, IL-6, and IL-1β, which can induce insulin resistance and contribute to stress hyperglycemia. Meanwhile, SFTS is associated with significant alterations in inflammatory and organ function parameters, many of which are closely linked to blood glucose metabolism. Therefore, hyperglycemia may reflect the overall inflammatory burden in SFTS; however, its relationship with these parameters remains insufficiently defined. While stress hyperglycemia is usually transient in otherwise healthy individuals, it may persist in the context of severe infectious diseases and reflect a heightened systemic stress response. Previous studies in critically ill and infectious disease populations have shown that stress hyperglycemia, or elevated blood glucose levels in the absence of pre-existing diabetes, is associated with unfavorable clinical outcomes.15 SFTS is characterized by pronounced inflammatory responses and multi-organ dysfunction, both of which are known to disrupt blood glucose homeostasis. In this context, blood glucose may serve as a readily accessible indicator of disease severity. However, evidence on this association in SFTS remains limited. To date, few studies have specifically examined stress hyperglycemia in patients with SFTS, and its relationship with disease severity and inflammatory responses has not been fully clarified. Therefore, this study aimed to systematically characterize blood glucose alterations in patients with SFTS and to explore their associations with disease severity and key laboratory parameters, including inflammatory cytokines, to provide potential reference indicators for disease assessment and risk stratification. Materials and Methods Patients and Control Participants This study analyzed 172 hospitalized patients diagnosed with SFTS caused by Dabie bandavirus infection at the Department of Infectious Diseases, Nanjing Drum Tower Hospital, between April 2022 and April 2025. The study received approval from the Institutional Review Board (IRB) of the Nanjing Drum Tower Hospital (approval no. 2025–0481-01), and the requirement for informed consent was waived due to its retrospective design. The study was conducted in accordance with the Declaration of Helsinki. All patients underwent testing for viral RNA using real-time reverse transcription polymerase chain reaction to confirm Dabie bandavirus infection. The patient cohort was categorized into survivors and non-survivors based on clinical outcomes. Severe cases were defined as those meeting any of the following criteria:16 multi-organ dysfunction, acute respiratory distress syndrome (ARDS), sepsis, disseminated intravascular coagulation (DIC), failure of one or more organs, infection-induced toxic shock, or death. The Sequential Organ Failure Assessment (SOFA) score and Charlson Comorbidity Index (CCI) were calculated at admission to evaluate organ dysfunction and comorbidity burden, respectively, according to established methods.17,18 Age- and sex-matched individuals from the Physical Examination Center were included as healthy controls. Clinical data were collected from the electronic medical record system using standardized forms. Healthy controls were included to provide reference values for baseline laboratory parameters. Unless otherwise specified, laboratory measurements were performed on blood samples obtained at admission, while dynamic changes were assessed using serial measurements during hospitalization. Detection and Collection of Clinical Parameters Serum biochemical parameters, including blood glucose (GLU), total cholesterol (TC), triglycerides (TG), high‑density lipoprotein cholesterol (HDL‑C), low‑density lipoprotein cholesterol (LDL‑C), apolipoprotein AI (ApoAI), apolipoprotein B (ApoB), albumin (ALB), urea nitrogen (UREA), creatinine (CREA), uric acid (UA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), C‑reactive protein (CRP), and ferritin were measured using standard automated analyzers (Beckman AU5400, Germany; Roche Cobas e801, Switzerland). CRP was determined by immunoturbidimetry, HbA1c by ion‑exchange high‑performance liquid chromatography (Bio‑Rad Laboratories, China), and ferritin by electrochemiluminescence immunoassay. Coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), and D‑dimer, were assessed using a Sysmex CS‑5100 analyzer, while complete blood counts and hematological indices were obtained with an automated hematology analyzer (Sysmex Corporation, Japan). Serum Dabie bandavirus levels were quantified via real‑time reverse transcription PCR on the Applied Biosystems ABI 7500 platform after automated nucleic acid extraction. Cytokines, including IL‑1β, IL‑2, IL‑4, IL‑5, IL‑6, IL‑8, IL‑10, IL‑12p70, IL‑17, IFN‑γ, IFN‑α, and TNF‑α, were measured by flow cytometry (EasyCell, Hangzhou Biogroup Technology Co). All laboratory procedures were performed in a certified Biosafety Level 2 (BSL-2) laboratory following standard biosafety regulations. No procedures involving live virus culture or isolation were conducted. All laboratory results were extracted from the hospital’s laboratory information and electronic medical record systems. The stress hyperglycemia ratio (SHR) was calculated according to a previously validated method as follows: SHR = admission blood glucose / (1.59 × HbA1c − 2.59).15 Statistical Analysis Continuous variables were expressed as mean ± standard deviation (SD) and compared between groups using Student’s t-test. Paired t-tests were used to compare changes in blood glucose levels between different time points within the same group. Categorical variables were compared using the chi-square test. Spearman correlation coefficients (r) were calculated to explore associations among clinical parameters, with statistical significance set at p<0.05. Variables showing statistical significance in univariate analysis were included in multivariate logistic regression models, with results reported as odds ratios (OR) and 95% confidence intervals (CI). All statistical analyses and data visualizations were performed using SPSS version 29.0 and GraphPad Prism version 8.3. Results Clinical Characteristics of Patients A total of 172 SFTS patients were enrolled, including 78 males and 94 females, with a mean age of 64.1 ± 11.4 years. The cohort comprised 140 survivors (81%) and 32 non-survivors (19%), as well as 42 (24%) severe cases and 130 (76%) mild cases. A total of 172 age- and sex-matched healthy individuals were included as controls, with no significant differences in age or sex between groups. Detailed baseline characteristics are presented in Table 1. Patients in the non-survival and severe groups had significantly higher SOFA scores and Charlson Comorbidity Index (CCI) values compared with those in the survival and mild groups (all P < 0.0001), indicating more severe organ dysfunction and a higher burden of comorbidities in these patients. Non-survivors had a shorter interval from symptom onset to hospital admission and exhibited significantly prolonged APTT, decreased platelet counts, and elevated levels of blood glucose, AST, LDH, CRP, urea, and creatinine compared with survivors. Consistent patterns were also observed when comparing severe and mild cases. Table 1Clinical and Laboratory Characteristics of SFTS Patients by Survival and Disease SeverityParametersHealthy ControlSFTS PatientsPSurvivalNon-survivalPMild SymptomsSevere SymptomsPNo.172172–14032–13042–Male/Female (n)80/9278/940.83*63/7715/170.85*60/7018/240.71*Age (years)63.3 ± 9.264.1 ± 11.40.4962.6 ± 11.470.8 ± 8.70.0762.1 ± 11.370.2 ± 9.20.12Time from onset to admission (days)–––10.2 ± 8.37.8 ± 4.3<0.00019.5 ± 6.710.5 ± 10.50.0001Time from admission to discharge or death–––11.7 ± 14.29.0 ± 9.80.3110.7 ± 13.212.8 ± 14.40.39SOFA score–––4.2 ± 3.310.9 ± 2.9<0.00013.8 ± 2.810.4 ± 3.8<0.0001CCI–––2.1 ± 1.66.0 ± 1.5<0.00011.9 ± 1.55.7 ± 1.6<0.0001Laboratory FindingsGlucose (mmol/L)4.9 ± 0.47.7 ± 3.1<0.00017.3 ± 3.09.2 ± 3.20.0017.0 ± 2.79.8 ± 3.3<0.0001HbA1c (%)5.5 ± 0.56.5 ± 1.2<0.00016.4 ± 1.26.6 ± 0.90.636.5 ± 1.26.5 ± 1.90.79WBC (×109/L)5.9 ± 1.24.2 ± 3.1<0.00014.2 ± 3.24.1 ± 2.50.134.1 ± 3.24.3 ± 2.70.19HGB (g/L)143.3 ± 14.8123.1 ± 22.7<0.0001121.8 ± 14.2128.7 ± 20.50.12122.4 ± 23.4125.2 ± 20.30.49APTT (s)24.2 ± 3.740.9 ± 16.0<0.000136.8 ± 12.358.3 ± 18.20.002535.5 ± 11.157.0 ± 17.7<0.0001PLT (×109/L)229.7 ± 59.976.0 ± 58.5<0.000183.6 ± 61.343.3 ± 26.5<0.000186.1 ± 60.545.5 ± 38.80.0016ALT (U/L)23.7 ± 12.192.9 ± 69.5<0.000183.8 ± 63.5132.0 ± 80.90.0682.7 ± 64.2123.9 ± 76.10.16AST (U/L)22.1 ± 5.9242.6 ± 266.8<0.0001172.7 ± 169.5541.9 ± 381.8<0.0001158.7 ± 154.7496.5 ± 361.0<0.0001LDH (U/L)174.4 ± 29.01110 ± 1412<0.0001783.6 ± 726.92509.0 ± 2448.2<0.0001718.8 ± 641.02294.4 ± 2234.8<0.0001ALB (g/L)46.1 ± 2.433.1 ± 4.6<0.000133.8 ± 4.429.9 ± 4.00.5334.0 ± 4.430.3 ± 3.90.39GLO (g/L)28.2 ± 3.628.6 ± 7.10.5628.1 ± 7.330.9 ± 5.90.1728.2 ± 7.429.8 ± 6.00.13UREA (mmol/L)5.6 ± 1.45.8 ± 3.70.584.9 ± 2.99.4 ± 4.5<0.00014.7 ± 2.68.8 ± 4.8<0.0001CREA (μmol/L)65.9 ± 15.976.9 ± 44.80.00367.8 ± 33.5117.1 ± 63.6<0.000165.6 ± 26.9117.1 ± 63.6<0.0001CRP (mg/L)2.0 ± 2.518.9 ± 31.4<0.000114.1 ± 24.840.1 ± 45.6<0.000113.5 ± 25.435.3 ± 40.9<0.0001IL-6 (pg/mL)3.1 ± 1.7121.1 ± 182.5<0.000192.7 ± 171.0234.9 ± 186.80.5576.6 ± 150.4230.1 ± 208.60.02Notes: Data are presented as mean ± SD. *P value was calculated using the chi-square test.Abbreviations: SOFA, sequential organ failure assessment; CCI, Charlson comorbidity index; WBC, white blood cell; HGB, Hemoglobin; APTT, activated partial thromboplastin time; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ALB, albumin; GLO, globulin; UREA, urea; CREA, Creatinine; CRP, C‑reactive protein. Clinical and Laboratory Characteristics of SFTS Patients by Survival and Disease Severity Notes: Data are presented as mean ± SD. *P value was calculated using the chi-square test. Abbreviations: SOFA, sequential organ failure assessment; CCI, Charlson comorbidity index; WBC, white blood cell; HGB, Hemoglobin; APTT, activated partial thromboplastin time; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ALB, albumin; GLO, globulin; UREA, urea; CREA, Creatinine; CRP, C‑reactive protein. Blood Glucose Metabolism Abnormalities in Patients with SFTS To investigate the characteristics and clinical significance of blood glucose metabolism in SFTS patients, we compared blood glucose and HbA1c levels between SFTS patients and healthy controls. Both blood glucose and HbA1c levels were significantly higher in SFTS patients compared with healthy controls (Figure 1A and B). After excluding patients with a history of diabetes, the admission blood glucose level in SFTS patients remained significantly higher than that in healthy controls, whereas no significant difference was observed in HbA1c levels (Figure 1C and D). These findings suggest that SFTS patients may present with stress hyperglycemia upon admission. Comparison of blood glucose and HbA1c levels between SFTS patients and healthy controls. Comparison of blood glucose (A) and HbA1c levels (B) between all SFTS patients and healthy controls, and comparison of blood glucose (C) and HbA1c levels (D) between non‑diabetic SFTS patients and healthy controls. Data are presented as mean ± standard. Verification of Stress Hyperglycemia in Patients with SFTS To further confirm the presence of stress hyperglycemia in SFTS patients, we calculated the stress hyperglycemia ratio (SHR) as previously described.16 We found that blood glucose, HbA1c, and SHR levels increased in parallel with viral load, and all three variables were significantly correlated with viral load (correlation coefficients > 0.3, P < 0.01; Figure 2A–C). After adjustment for HbA1c, SHR levels in SFTS patients remained significantly higher than those in healthy controls (Figure 2D), further confirming the presence of marked stress hyperglycemia in SFTS patients. Confirmation of stress hyperglycemia in SFTS. Correlation of blood glucose (A), HbA1c (B), and SHR (C) levels with viral load in SFTS patients, and comparison of SHR levels between SFTS patients and healthy controls (D). Data are presented as mean ± standard deviation; correlations were analyzed using Spearman correlation coefficients. Association of Blood Glucose and SHR with Disease Severity and Outcomes in SFTS To evaluate the relationship between blood glucose levels and disease progression or outcomes in SFTS patients, we stratified patients by disease severity and survival status. Both admission blood glucose and SHR levels were significantly higher in severe cases compared with mild cases (Figure 3A and B). Further analysis revealed that non‑survivors had markedly higher blood glucose and SHR levels than survivors (Figure 3C and D). Multivariable logistic regression analysis (Table S1) showed that the association between SHR and clinical outcomes was attenuated after adjustment for confounding factors and did not reach statistical significance. These findings indicate a potential association between elevated blood glucose and disease progression and adverse clinical outcomes in SFTS patients, while the independent effects of both blood glucose and SHR remain to be clarified. Blood glucose and SHR levels by disease severity and survival status in SFTS patients. Comparison of admission blood glucose (A) and SHR (B) levels between mild and severe SFTS cases, and comparison of admission blood glucose (C) and SHR (D) levels between survivor and non‑survivor SFTS patients. Data are presented as mean ± standard deviation. Dynamic Changes in Blood Glucose Levels and Their Relationship with Adverse Clinical Outcomes To further assess the impact of blood glucose changes on prognosis, we continuously monitored dynamic blood glucose levels in survivors and non‑survivors. In non‑survivors, no significant difference was observed between admission and overall follow‑up blood glucose levels, with some patients showing an increasing trend during the disease course (Figure 4A). In contrast, survivors exhibited a significant decline in blood glucose levels over time compared with admission values (Figure 4B). Analysis of blood glucose dynamics by admission day (Figure 4C) demonstrated that non‑survivors consistently had higher blood glucose levels than survivors, with an overall upward trend, whereas blood glucose levels in survivors remained relatively stable. Dynamic changes in blood glucose levels and their relationship with clinical outcomes. Changes in blood glucose levels at admission and during follow‑up in non‑survivors (A). Statistical analysis using paired t‑test. Changes in blood glucose levels at admission and during follow‑up in survivors (B). Statistical analysis using paired t‑test. Dynamic changes in blood glucose levels in survivors and non‑survivors according to hospitalization duration (C). Data are presented as mean ± standard error. Correlation Between Blood Glucose Levels, Clinical Laboratory Parameters, and Cytokines In the context of viral infection, various clinical laboratory indicators undergo significant alterations, which may be associated with both disease severity and blood glucose levels. These selected parameters reflect key pathophysiological processes in SFTS, including inflammation, organ dysfunction, coagulation abnormalities, and metabolic status, which are closely linked to stress hyperglycemia. To further elucidate the clinical implications of blood glucose in SFTS patients, we analyzed its correlation with multiple key laboratory parameters. Blood glucose levels showed significant positive correlations with UREA, UA, CREA, APTT, and AST, and significant negative correlations with ALB, ApoAI, HDL, and PLT (Figure 5A–I). Additionally, blood glucose levels were significantly correlated with multiple pro‑inflammatory cytokines, including IL‑1β, IL‑5, IL‑12p70, IL‑17, IL‑2, IL‑4, TNF‑α, and IL‑6 (Figure 6A–H). These findings suggest that blood glucose levels are not only associated with conventional clinical laboratory parameters but also associated with inflammatory mediators, underscoring their potential value in evaluating disease severity in SFTS patients. Correlation between blood glucose levels and clinical laboratory parameters in SFTS patients. Correlation of blood glucose levels with UREA (A), UA (B), CREA (C), APTT (D), AST (E), PLT (F), ALB (G), HDL (H), and ApoAI (I). Correlations were analyzed using Spearman correlation coefficients. Data are presented as mean ± standard deviation. Correlation between blood glucose levels and serum cytokines in SFTS patients. Correlation of blood glucose levels with IL 1β (A), IL 5 (B), IL 12p70 (C), IL 17 (D), IL 2 (E), IL 4 (F), TNF α (G), and IL 6 (H). Correlations were analyzed using Spearman correlation coefficients. Data are presented as mean ± standard deviation. We also calculated SHR by adjusting blood glucose with glycated hemoglobin. SHR was significantly correlated with key clinical parameters such as AST, LDH, APTT, Ferritin, ALT, D‑dimer, UREA, and PLT (Figure S1), and additionally showed significant associations with several inflammatory cytokines, including IFN‑α, IFN‑γ, IL‑17 and IL‑6 (Figure S2). Discussion This study found that patients with SFTS commonly exhibited elevated blood glucose levels, which were significantly associated with disease severity, suggesting potential clinical relevance in disease progression. However, a single admission blood glucose measurement cannot fully distinguish the contributions of baseline blood glucose metabolism from those of acute stress responses, especially in patients with pre-existing diabetes or latent blood glucose intolerance. In recent years, SHR has been proposed as a more precise indicator for assessing stress-induced hyperglycemia. By adjusting for baseline blood glucose levels, SHR provides a more accurate reflection of the magnitude of blood glucose elevation caused by acute stress. Our findings demonstrated increased SHR in patients with SFTS, further suggesting that hyperglycemia in these patients primarily arises from acute stress responses rather than from chronic metabolic abnormalities. It should be noted that HbA1c reflects long-term glycemic status rather than acute metabolic changes. The higher HbA1c observed in SFTS patients may indicate a greater prevalence of underlying dysglycemia or unrecognized impaired blood glucose metabolism. Notably, after excluding patients with known diabetes, HbA1c levels were no longer significantly different between groups, whereas admission blood glucose remained elevated. This supports that the observed hyperglycemia is predominantly stress-related. Stress induced hyperglycemia is a common metabolic alteration in critical illness, frequently observed in sepsis, acute cardiovascular and cerebrovascular events, and various viral infections.19,20 Although stress hyperglycemia has been well described in severe sepsis,21 SFTS differs from bacterial sepsis in its viral etiology and prominent cytokine-driven immune response. These features may influence metabolic regulation during acute illness. In addition, SFTS is characterized by profound immune dysregulation, cytokine storm, thrombocytopenia, and multiorgan involvement, which may create a distinct metabolic and inflammatory milieu compared with bacterial sepsis or other critical illnesses. Our findings suggest that SHR may better reflect stress-related hyperglycemia and its association with inflammation and disease severity in SFTS than admission blood glucose alone. The underlying mechanisms involve multiple neuroendocrine and immune-inflammatory pathways: during acute infection and systemic inflammation, activation of the hypothalamic–pituitary–adrenal axis and sympathetic nervous system lead to increased secretion of cortisol, epinephrine, and norepinephrine, promoting hepatic gluconeogenesis and glycogenolysis. Meanwhile, pro-inflammatory cytokines such as IL‑1β, IL‑6, and TNF‑α contribute to peripheral insulin resistance, collectively driving blood glucose elevation.22 Thus, the observed hyperglycemia in SFTS patients likely reflects a systemic stress response to viral infection and inflammatory insults. Further analysis revealed that blood glucose levels were significantly correlated not only with laboratory indicators such as UREA, CREA, APTT, and ALB but also positively with multiple pro-inflammatory cytokines, including IL‑1β, IL‑6, and TNF‑α. These findings highlight a potential link between hyperglycemia, cytokine storm, and multiorgan dysfunction in SFTS. On one hand, cytokines can exacerbate insulin resistance and gluconeogenesis through multiple mechanisms: IL‑1β promotes pancreatic β-cell apoptosis and inhibits insulin secretion, IL‑6 disrupts insulin signaling pathways, and TNF‑α interferes with blood glucose uptake via the JNK pathway.23,24 Although IL-4 is generally considered an anti-inflammatory cytokine, its positive correlation with blood glucose in this study may reflect a compensatory anti-inflammatory response during the cytokine storm. This suggests that both pro- and anti-inflammatory pathways are activated simultaneously in SFTS. On the other hand, hyperglycemia itself can amplify inflammatory responses and tissue injury by increasing oxidative stress, impairing endothelial function, and suppressing lymphocyte proliferation and phagocytic activity.25 This suggests that hyperglycemia in SFTS is not merely a passive marker of disease severity but may actively participate in the amplification of inflammation and organ damage, forming a vicious cycle of “hyperglycemia–inflammation–organ injury”. Our research group has previously reported that disturbances in lipid metabolism, such as reduced HDL-c and ApoAI levels, as well as elevated serum calprotectin reflecting innate immune activation, are associated with disease severity and prognosis in SFTS.26,27 Distinct from previous studies mainly focusing on lipid metabolism and inflammatory biomarkers in SFTS, the present study evaluates stress-related blood glucose dysregulation and introduces SHR to better distinguish acute stress hyperglycemia from baseline glycemic status. By incorporating the SHR to account for baseline glycemic status, we demonstrate that acute hyperglycemia is closely associated with disease severity, inflammatory responses, and adverse outcomes. These findings extend our previous observations by highlighting stress hyperglycemia as a clinically relevant metabolic alteration associated with disease severity and inflammatory responses in SFTS, complementing lipid and inflammatory biomarkers. From a clinical perspective, elevated blood glucose levels in SFTS were closely associated with disease severity, consistent with findings from other viral infections. For instance, in dengue, influenza, and COVID‑19, admission hyperglycemia has been significantly associated with higher ICU admission rates, organ dysfunction, and mortality.28–30 Therefore, blood glucose monitoring may serve as a convenient biomarker reflecting disease severity and clinical status in SFTS, especially in primary or resource-limited hospital settings. Moreover, our findings provide potential insights for SFTS management strategies. Previous studies have demonstrated that active control of stress hyperglycemia in critically ill patients can improve outcomes and reduce infection and multi-organ dysfunction.31,32 Although glycemic control, including insulin therapy,33 is routinely applied in clinical practice for SFTS patients with hyperglycemia, high-quality prospective or randomized interventional studies specifically targeting hyperglycemia in SFTS remain limited. Therefore, whether glycemic management influences clinical outcomes in SFTS remains unclear and warrants further investigation in well-designed prospective studies. This study has several limitations. It was a retrospective analysis with a limited sample size, which may have reduced the statistical power of the multivariate analysis and, together with potential collinearity among variables, contributed to the lack of significant findings in the adjusted models. In addition, HbA1c was measured only once during hospitalization, precluding assessment of dynamic changes in SHR. The effects of antiviral therapy and supportive treatments on blood glucose levels were not explored. Future prospective studies with larger sample sizes and dynamic blood glucose monitoring are needed to further clarify the clinical significance of stress hyperglycemia in SFTS. Conclusion In conclusion, this study shows that stress hyperglycemia is common in patients with SFTS and is associated with inflammatory responses and disease severity. Blood glucose and SHR may serve as readily available markers reflecting disease severity and inflammatory status in SFTS. Further prospective studies are needed to clarify the clinical significance of stress hyperglycemia and its potential implications for patient management. Acknowledgments This work was supported by Clinical Research Project of Jiangsu Provincial Health Commission (M2025011), The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ethical Considerations This study was approved by the Institutional Review Board (IRB) of the Nanjing Drum Tower Hospital (approval no. 2025-0481-01). Informed consent was waived due to the retrospective nature of this study. Patient data were anonymized to ensure confidentiality and this research complies with the requirements of the Declaration of Helsinki. Disclosure The author(s) report no conflicts of interest in this work. References